BD Issues Update to Voluntary Global Recall of Alaris™ and BD Alaris™ Pump Modules Serviced with Legacy Bezel Kit Assemblies

FRANKLIN LAKES, N.J. (July 15, 2025) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued a voluntary recall related to certain Alaris™ and BD Alaris™ Pump Modules that may have been serviced with previously recalled bezel kit assemblies.

BD is issuing this voluntary recall notice to reiterate that certain bezel kit assemblies that were manufactured between April 2011 and June 2017 and previously recalled in 2019 should not be used for service with the Alaris™ and BD Alaris™ Pump Module.

BD became aware via customer complaints of customer/third party usage of affected bezel kit assemblies to service Alaris™ and BD Alaris™ Pump Modules. These affected bezel kit assemblies were manufactured with a specific type of plastic material that weakens over time, leading to the potential of separated and/or broken bezel bosses that can cause free flow, over infusion, under infusion or interruption of infusion. This recall has been associated with incidents of serious injury and patient death.

The previous field action impacted bezel kit assemblies manufactured with the specific type of plastic material (FR-110 bezels) and used to service Alaris™ and BD Alaris™ Pump Modules (8100). However, as pump modules not originally manufactured with the affected bezel assembly may have been serviced by customers or a third party with the recall-affected bezel spare part, this recall is inclusive of all Alaris™ and BD Alaris™ Pump Modules.

BD is instructing customers to immediately dispose of any affected bezel kit assemblies remaining in their possession. BD is also instructing customers to check their records to determine if any of their pump modules may have been serviced with affected bezel kit assemblies and if so, to perform a visual inspection of the bezel. If an affected bezel is found, the pump should be removed from service and customers should contact BD for further instructions.

Information about this recall is available on BD’s website or by calling BD at 1-888-562-6018. In addition, this updated notification will be sent to all customers starting July 15, 2025.

Customers should report any complaints experienced with the use of this product to the BD Complaint Center at 1-844-823-5433, Monday – Friday between the hours of 9 a.m. and 6 p.m. ET or by emailing productcomplaints@bd.com.  

FDA MedWatch Reporting

Adverse reactions/events experienced with the use of this product should be reported to the FDA’s MedWatch Program by:

• Online: Complete and submit the report at www.fda.gov/medwatch/report.htm
• Call 1-800-FDA-1088 (1-800-332-1088)
• Regular Mail: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:                                                                                                      Investors:

Troy Kirkpatrick                                                                                       Adam Reiffe

VP, Public Relations                                                                                Sr. Director, Investor Relations

858.617.2361                                                                                         201.847.6927        

troy.kirkpatrick@bd.com                                                                     adam.reiffe@bd.com